In this update of small molecules in the news we will cover recent:
- (B)Million Dollar Molecules: recent mergers and acquisitions
- Molecules in Motion: clinical trial updates and FDA filings
- Molecules of the Month – Where Are They Now?: updates on past Drug Hunter MotM
- Potential upcoming approvals: recent NDA filings and upcoming PDUFA dates
Want updates like this straight to your inbox? Sign up for our weekly newsletter here.
Million-Dollar Molecules
baxdrostat
This highly selective, oral aldosterone synthase (CYP11B2) inhibitor is being acquired by AstraZeneca via CinCor in a $1.8B transaction. The molecule is in several Ph. II trials (0.5-2 mg QD) for hypertension, CKD, and primary aldosteronism, appears to have demonstrated dose-dependent PK/PD and blood pressure response, and appears to be well-tolerated so far. CinCor licensed the molecule from Roche (RO6836191).
request a trial
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
